CC
PRDS

Cannell Capital’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Cannell Capital’s Portfolio PRDS Stock Details PRDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-16,132
Closed -$21.3K – 95
2023
Q1 		$21.3K Hold
16,132
– – ﹤0.01% 86
2022
Q4 		$27.3K Hold
16,132
– – 0.01% 85
2022
Q3 		$30K Buy
16,132
+12,173
+307% +$36.3K 0.01% 88
2022
Q2 		$12K Buy
+3,959
New +$24.2K ﹤0.01% 74

Other funds holding PRDS

FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VS
VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

Cannell Capital's PRDS Position: Q2 2023 in Review

Cannell Capital sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q2 2023, closing a stake of 16,132 shares — an estimated $21.3K sold.

Cannell Capital first reported a position in PRDS in Q2 2022 and held it in 4 quarters. The position peaked at $30K in Q3 2022. 59 funds tracked by Wall St. Rank hold PRDS as of Q2 2023.

  • Cannell Capital reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Cannell Capital sold 16,132 Pardes Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $21.3K.
  • Cannell Capital first reported a position in Pardes Biosciences, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
  • Cannell Capital's Pardes Biosciences, Inc. Common Stock position peaked at $30K in Q3 2022.
  • 59 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q2 2023.

Based on Cannell Capital's 13F filing for Q2 2023, filed 14 Aug 2023.